文献速递皮肤肿瘤

SIRT1与SIRT3双重抑制在BrafV600E/PtenNULL小鼠中的抗黑色素瘤作用

Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice.
PubMed 文献 · J Invest Dermatol · 2021-09-29

本研究在BrafV600E/PtenNULL小鼠模型中评估SIRT1/SIRT3双重抑制剂4'-溴白藜芦醇(4'-BR)的抗黑色素瘤疗效。4'-BR(5–30 mg/kg腹腔注射,每周3天,共5周)在30 mg/kg剂量下显著缩小原发瘤体积并减少肺转移,且未观察到不良反应。机制上肿瘤增殖、生存及进展标志物受调控,免疫相关基因表达谱亦发生显著改变。

要点

  • 4'-BR在30 mg/kg剂量下显著减小原发黑色素瘤大小和体积并减少肺转移。
  • 4'-BR对增殖、生存和黑色素瘤进展标志物有显著调节作用。
  • 4'-BR显著下调转移促进、趋化因子/细胞因子调节及固有/适应性免疫相关基因。

核心结论

  • 4'-BR抑制SIRT1和SIRT3具有抗黑色素瘤、抗转移和免疫调节活性,值得进一步研究包括临床研究。

研究设计与样本

  • 在10周龄BrafV600E/PtenNULL小鼠剃毛背部局部涂抹4-羟基他莫昔芬诱导肿瘤,模拟人类疾病包括转移。
  • 4'-BR以5–30 mg/kg体重腹腔注射,每周3天,共5周,评估对黑色素瘤发生和进展的影响。

主要发现

  • 4'-BR在30 mg/kg剂量下显著减小原发黑色素瘤肿瘤大小和体积,并减少肺转移,无不良反应。
  • 机制研究显示肿瘤中增殖、生存和黑色素瘤进展标志物发生显著调节。
  • 使用PanCancer Immune Profiling Panel(770个基因)的差异基因表达分析显示,4'-BR显著下调转移促进、趋化因子/细胞因子调节及固有/适应性免疫功能相关基因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapeutic strategies are required for the effective and lasting treatment of metastatic melanoma, one of the deadliest skin malignancies. In this study, we determined the antimelanoma efficacy of 4'-bromo-resveratrol (4'-BR), which is a small-molecule dual inhibitor of SIRT1 and SIRT3, in a BrafV600E/PtenNULL mouse model that recapitulates human disease, including metastases. Tumors were induced by topical application of 4-hydroxy-tamoxifen on shaved backs of mice aged 10 weeks, and the effects of 4'-BR (5‒30 mg/kg of body weight, intraperitoneally, 3 days per week for 5 weeks) were assessed on melanoma development and progression. We found that 4'-BR at a dose of 30 mg/kg significantly reduced the size and volume of primary melanoma tumors as well as lung metastasis with no adverse effects. Furthermore, mechanistic studies on tumors showed significant modulation in the markers of proliferation, survival, and melanoma progression. Because SIRT1 and SIRT3 are linked to immunomodulation, we performed differential gene expression analysis using a PanCancer Immune Profiling Panel (770 genes). Our data showed that 4'-BR significantly downregulated the genes related to metastasis promotion, chemokine/cytokine regulation, and innate/adaptive immune functions. Overall, inhibition of SIRT1 and SIRT3 by 4'-BR is a promising antimelanoma therapy with antimetastatic and immunomodulatory activities warranting further detailed studies, including clinical investigations.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Chhabra G, Singh CK, Guzmán-Pérez G, et al. Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice. J Invest Dermatol. 2021. PMID: 34597611. doi:10.1016/j.jid.2021.08.434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。